Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
File:Mechanism imatinib.jpg - Wikimedia Commons
FDA licences imatinib mesylate for CML - The Lancet Oncology
Imatinib - Wikipedia
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions
Imatinib: the narrow line between immune tolerance and activation: Trends in Molecular Medicine
Journal of Biomedical and Pharmaceutical Research
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Mechanism of action of imatinib mesylate (Gleevec ® ). Imatinib... | Download Scientific Diagram
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia - Chorzalska - 2018 - Molecular Oncology - Wiley Online Library
Mechanism of action of Imatinib; Imatinib binds to the ATP binding site... | Download Scientific Diagram
PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar
Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment – Implications to its mechanism of action - ScienceDirect